Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients
May 1, 2014, 00:00
10.1016/j.jval.2014.03.1709
https://www.valueinhealthjournal.com/article/S1098-3015(14)01760-4/fulltext
Title :
Assessing The Likely Cost-Utility Of Alemtuzumab Versus Rabbit Anti-Thymocte Globulin As Induction Therapy For High-Risk Kidney Transplant Recipients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)01760-4&doi=10.1016/j.jval.2014.03.1709
First page :
A294
Section Title :
Urinary/Kidney Disorders
Open access? :
No
Section Order :
1207